Colorectal
1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
CorreGeneChina - Beijing
1 program1
KRAS-specific Autologous TCR-T cell injectionPhase 11 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
CorreGeneKRAS-specific Autologous TCR-T cell injection
Temple TherapeuticsGeneric Print Intervention
Clinical Trials (2)
Total enrollment: 221 patients across 2 trials
KRAS-Specific Autologous TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors
Start: Feb 2025Est. completion: Dec 20288 patients
Phase 1Active Not Recruiting
Colorectal Cancer Screening Intervention for Family Members of Colorectal Cancer Patients
Start: Jun 2003Est. completion: May 2008213 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.